2.03

6.28% 0.12

After Hours: 2.03

Biomea Fusion Inc (BMEA)

Overview News Price History Option Chain Financials Why BMEA Down? Discussions Forecast

Biomea Fusion Inc stock is traded at $2.03, with a volume of 3.28M. It is up +6.28% in the last 24 hours and up +65.04% over the past month. Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Previous Close:

$1.91

Open:

$1.9

24h Volume:

3.28M

Relative Volume:

2.83

Market Cap:

$147.14M

Revenue:

Net Income/Loss:

$-44.95M

P/E Ratio:

-2.2745

EPS:

-0.8925

Net Cash Flow:

$-56.37M

1W Performance:

+17.34%

1M Performance:

+65.04%

6M Performance:

+46.04%

1Y Performance:

+10.93%

1-Day Range:

$1.885

$2.05

1-Week Range:

$1.6709

$2.05

52-Week Range:

$0.8719

$2.99

Biomea Fusion Inc Stock (BMEA) Company Profile

Name

Biomea Fusion Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(650) 980-9099

Address

1599 INDUSTRIAL ROAD, SAN CARLOS

Employee

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

BMEA's Discussions on Twitter

Compare BMEA vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMEA Biomea Fusion Inc	2.03	98.58M	0	-44.95M	-56.37M	-0.8925
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-26	Initiated	Rodman & Renshaw	Buy
Aug-28-25	Initiated	Jefferies	Buy
Jun-03-25	Resumed	Piper Sandler	Overweight
Oct-09-24	Initiated	Edward Jones	Buy
Sep-27-24	Upgrade	Rodman & Renshaw	Neutral → Buy
Sep-27-24	Upgrade	Truist	Hold → Buy
Aug-29-24	Initiated	CapitalOne	Overweight
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-24	Initiated	Truist	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight
Mar-29-23	Reiterated	Oppenheimer	Outperform
Mar-28-23	Reiterated	H.C. Wainwright	Buy
Feb-24-23	Initiated	Citigroup	Buy
Jun-02-22	Resumed	H.C. Wainwright	Buy
Jan-12-22	Initiated	H.C. Wainwright	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
May-11-21	Initiated	JP Morgan	Overweight
May-11-21	Initiated	Jefferies	Buy
May-11-21	Initiated	Piper Sandler	Overweight

View All

Biomea Fusion Inc Stock (BMEA) Latest News

Sep 04, 2026

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright - Yahoo Finance

Sep 04, 2026

Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next - TipRanks

Sep 04, 2026

Sep 03, 2026

Biomea Fusion to Participate in Upcoming Investor Conferences - investingnews.com

Sep 03, 2026

Sep 01, 2026

BMEA Surges 6.85%: Biomea Fusion Approaches Key $1.88 ResistanceQuote Data - vinanet.vn

Sep 01, 2026

Aug 29, 2026

BMEA Should I Buy - Intellectia AI

Aug 29, 2026

Aug 27, 2026